Previous 10 | Next 10 |
Avalo Therapeutics press release ( NASDAQ: AVTX ): Q2 GAAP EPS of -$1.38 beats by $0.37 . Revenue of $1.03M (-69.3% Y/Y) beats by $0.29M . For further details see: Avalo Therapeutics GAAP EPS of -$1.38 beats by $0.37, revenue of $1.03M beats by $0.29M
Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in August Dosed first patient in the Phase 2 PEAK Trial of its anti-LIGHT monoclonal antibody (AVTX-002) for the treatment of non...
WAYNE, Pa. and ROCKVILLE, Md., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of...
Avalo Therapeutics ( NASDAQ: AVTX ) said it was granting worldwide, exclusive license rights to Apollo Therapeutics to develop, manufacture and commercialize monoclonal antibody product AVTX-007 (camoteskimab). In January, Avalo had said it was discontinuin...
Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments. Apollo to lead continued clinical development of AVTX-007, currently in Phase 1b ROCKVILLE, Md. and CAMBRIDGE, United Kingdom, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeu...
Avalo Therapeutics ( NASDAQ: AVTX ) announced a one-for-twelve reverse stock split of the company’s common stock, par value $0.001, which will be effective on July 7, 2022. Stock will trade on split-adjusted basis beginning on July 8, 2022. The reverse stock spl...
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022. The C...
WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 4:00 PM ET at the M...
Avalo Therapeutics (NASDAQ:AVTX) said the first patient was dosed in a mid stage study of AVTX-002 to treat non-eosinophilic asthma (NEA). The phase 2 trial, dubbed PEAK, will enroll ~80 patients and who will receive either AVTX-002 or placebo, for treating poorly controlled NEA. Th...
WAYNE, Pa. and ROCKVILLE, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the S...
News, Short Squeeze, Breakout and More Instantly...
Avalo Therapeutics Inc. Company Name:
AVTX Stock Symbol:
NASDAQ Market:
Avalo Therapeutics Inc. Website:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
2024-07-06 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...